非布司他是哪个公司产的？

It is commonly used to treat hyperuricemic diseases with gout symptoms. This is a xanthine oxidase inhibitor that achieves efficacy by reducing serum uric acid. Which company makes nafebuxostat?

Febuxostat Manufacturer: Teijin Pharmaceuticals

Febuxostat is a new and highly effective selective inhibitor of non-purine xanthine oxidase, a key enzyme that promotes uric acid production.

Febuxostat is the latest XOR inhibitor developed in the world. It acts highly selectively on this oxidase to reduce the synthesis of uric acid in the body and reduce the concentration of uric acid, thereby effectively treating ventilation diseases. 

  Among drugs that inhibit uric acid production, colchicine is mainly used in the acute phase (acute phase). Compared with febuxostat, it is mainly allopurinol. Compared with allopurinol, febuxostat has the following advantages in addition to having fewer side effects:

1. Allopurinol only inhibits the reduced XOR, while febuxostat has a significant inhibitory effect on both the oxidized and reduced XOR, so its effect of reducing uric acid is more powerful and lasting;

2. Since allopurinol is a purine analogue, it will inevitably affect the activities of other enzymes involved in purine and pyridine metabolism. Therefore, repeated high-dose administration is required to maintain high drug levels during allopurinol treatment. This also leads to serious or even fatal adverse reactions due to drug accumulation. Febuxostat is a non-purine XOR inhibitor and therefore has a better safety profile.

(Alias: Febuxostat) can reduce the level of uric acid in the blood of gout patients with hyperuricemia. The dosage of febuxostat is 40 mg or 80 mg once a day, but this product is not recommended for gout patients without hyperuricemia.

Recommended related hot articles: /newsDetail/74703.html